

# References

## Chapter 40

- 1 Arlett PR, Kurz X. New approaches to strengthen pharmacovigilance. *Drug Discovery Today: Technologies*. 2011;**8**:e15–19.
- 2 Bégau B, Péré JC, Miremont G. Estimation of the denominator in spontaneous reporting. In: ARME-P Editions. *Methodological Approaches in Pharmacoepidemiology*. Amsterdam, Elsevier, 1993: 51–70.
- 3 Bégau B. Statistical methods of evaluating pharmacovigilance data. In: Mann AE, ed. *Pharmacovigilance*. Chichester, John Wiley & Sons, 2007: 257–64.
- 4 European Commission. A Guideline on Summary of Product Characteristics. Available from: [http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc\\_guideline\\_rev2\\_en.pdf](http://ec.europa.eu/health/files/eudralex/vol-2/c/smpc_guideline_rev2_en.pdf) (last accessed 18 November 2015).
- 5 European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP): Module VIII – Post-Authorisation Safety Studies. Available from: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document\\_listing/document\\_listing\\_000345.jsp&mid=WC0b01ac058058f32c](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c) (last accessed 18 November 2015).
- 6 Martin K, Bégau B, Latry P, Miremont-Salame G, Fourrier A, Moore N. Differences between clinical trials and postmarketing use. *British Journal of Clinical Pharmacology*. 2004;**57**:86–92.
- 7 European Medicines Agency. Guideline on Good Pharmacovigilance Practices (GVP): Module XVI – Risk Minimisation Measures: Selection of Tools and Effectiveness Indicators. Available from: [http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document\\_listing/document\\_listing\\_000345.jsp&mid=WC0b01ac058058f32c](http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000345.jsp&mid=WC0b01ac058058f32c) (last accessed 18 November 2015).
- 8 Sartor F, Walckiers D. Estimate of disease prevalence using drug consumption data. *American Journal of Epidemiology*. 1995;**141**:782–7.
- 9 Schneeweiss S, Avorn J. Postmarketing studies of drug safety. *British Medical Journal*. 2011;**342**:d342.
- 10 Leal I, Romio SA, Schuemie M, Oteri A, Sturkenboom M, Trifirò G. Prescribing pattern of glucose lowering drugs in the United Kingdom in the last decade: a focus on the effects of safety warnings about rosiglitazone. *British Journal of Clinical Pharmacology*. 2013;**75**(3):861–8.
- 11 Ehrenstein V, Hernandez RK, Ulrichsen SP, Rungby J, Lash TL, Riis AH, et al. Rosiglitazone use and post-discontinuation glycaemic control in two European countries, 2000–2010. *British Medical Journal Open*. 2013;**3**(9):e003424.
- 12 Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. *New England Journal of Medicine*. 2007;**356**:2457–71.
- 13 Abbing-Karahagopian V, Kurz X, de Vries F, van Staa TP, Alvarez Y, Hesse U, et al. Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT project. *Current Clinical Pharmacology*. 2014;**9**:130–8.
- 14 Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. *American Journal of Epidemiology*. 2003;**158**:915–20.
- 15 Macias Saint-Gerons D, de la Fuente HC, Montero CD, Gil MJ, de Andres-Trelles F, Catala-Lopez F. Standard and intensive lipid-lowering therapy with statins for the primary prevention of vascular diseases: a population-based study. *European Journal of Clinical Pharmacology*. 2014;**70**:99–108.
- 16 Khong TP, de Vries F, Goldenberg JS, Klungel OH, Robinson NJ, Ibanez L, Petri H. Potential impact of benzodiazepine use on the rate of hip fractures in five large European countries and the United States. *Calcified Tissue International*. 2012;**91**:24–31.